Table 1. Characteristics of included studies.

Study	Country	Sample size (n)	Gender (M/F) (n)	GHET1 expression (H/L) (n)	Detection method	Cut-off value	Cancer	Outcomes	NOS
Guan (2017) [12]	China	52	40/12	25/27	qRT-PCR	Median	NSCLC	CP, OS	7
Jin (2017) [13]	China	68	35/33	27/41	qRT-PCR	Mean	HCC	CP, OS	7
Li (2014) [14]	China	80	43/37	39/41	qRT-PCR	Median	Bladder cancer	CP, OS	7
Liu (2017) [16]	China	55	34/21	28/27	qRT-PCR	Median	ESCC	CP	6
Liu (2018) [15]	China	86	61/25	43/43	qRT-PCR	Median	HNC	CP,OS	7
Shen (2018) [17]	China	105	44/61	53/52	qRT-PCR	Median	NSCLC	CP, OS, PFS	7
Song (2018) [18]	China	60	0/60	30/30	qRT-PCR	Median	Breast cancer	CP, OS	7
Xia (2018) [19]	China	42	28/14	21/21	qRT-PCR	Median	Gastric cancer	CP	6
Yang (2014) [20]	China	42	31/11	21/21	qRT-PCR	Median	Gastric cancer	CP, OS	7
Zhou (2017) [21]	China	64	34/30	36/28	qRT-PCR	Median	Pancreatic cancer	CP	6

Abbreviations: CP, clinicopathological parameter; F, female; H, high GHET1 expression; L, low GHET1 expression; M, male.